Emibetuzumab, formerly known as LY2875358, represents a novel treatment method in oncology, specifically targeting the HGF Receptor tyrosine kinase. This recombinant immunoglobulin works by primarily binding to the https://nicolespzl832356.wikicorrespondence.com/user